# The Safety/Efficacy Of Daratumumab With Belatacept In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation

> **NCT05145296** · PHASE2 · TERMINATED · sponsor: **University Hospital, Grenoble** · enrollment: 5 (actual)

## Conditions studied

- Sensitisation
- Highly Sensitised Dialysis Patients

## Interventions

- **COMBINATION_PRODUCT:** Each patient will undergo in the first step of the study belatacept treatment and in the second apheresis and daratumumab

## Key facts

- **NCT ID:** NCT05145296
- **Lead sponsor:** University Hospital, Grenoble
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-19
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-10-10
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** limited clinically significant reduction on global cPRA levels (access to transplantation was unchanged), as well as restrictions in belatacept supply.
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05145296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05145296, "The Safety/Efficacy Of Daratumumab With Belatacept In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05145296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*